



TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

March 9, 2022

Company conference call and webcast at 4:30 PM ET

AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the fourth quarter of 2021 on Thursday, March 24, 2022, at the close of the U.S. financial markets.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investors will follow management's remarks.

Conference Call and Webcast Information

The Company will host a conference call on Thursday, March 24, 2022, at 4:30 PM ET to review the clinical, corporate and financial highlights. To participate in the conference call, either join the webcast or dial one of the following numbers prior to the start of the call:

Domestic Dial-In Number: Toll-Free: 1-877-407-3982

International Dial-In Number: 1-201-493-6780

Conference ID: 13726816

The call will also be webcast live and can be accessed on TFF Pharmaceuticals' Website, <https://tffpharma.com> or directly by clicking [here](#). Please access the webcast at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company's website in the Events Calendar of the Investors section.

About TFF Pharmaceuticals' Thin Film Freezing Technology Platform

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by over 120 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at <https://tffpharma.com>.

SAFE HARBOR

This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its collaboration and referral arrangement with Catalent, the benefits of the Company's TFF platform and the Company's plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not achieve the favorable results expected from its collaboration and referral agreement with Catalent, (ii) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section "Risk Factors" included in the Company's 2020 Annual Report on Form 10-K filed with the SEC on March 10, 2021. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

TFF Pharmaceuticals Investor Relations Contact:

Corey Davis, Ph.D.

LifeSci Advisors

cdavis@lifesciadvisors.com

212-915-2577

TFF Pharmaceuticals Media Contact:

Gwendolyn Schanker

LifeSci Communications

(269) 921-3607

gschanker@lifescicomms.com

Source: TFF Pharmaceuticals, Inc.



Source: TFF Pharmaceuticals, Inc.